Value co-creation in healthcare: evidence from innovative therapeutic alternatives for hereditary angioedema

Table 6 Value co-creation in C1-INH-HAE

		Strategy 1 (home-based)			Strategy 2 (hospital-based)
Actors	Objectives	Activities	Partecipation to the value creation process	Value obtained	Activities	Partecipation to the value creation process	Value obtained
Focal	Cost vs quality	Offers the therapy at hospital	Active	(increased)public health due to increased compliance, but less medical costs per attack other than drugs due to treatment at home	Offers the therapy at hospital	Active	Public health
Other market facing	Sales	Provides the drug and the training for patients and caregivers	Active	(increased) profits due to increased compliance	Provides the drug	Active	Profits
Public	Cost vs quality	Funds the focal firm	Active	(increased) public health due to increased compliance, but less medical costs per attack due to treatment at home. (increased) social value due to less non-medical costs per attack	Funds the focal firm	Active	Public health
Personal	Quality	Involved in self-administration	Active	Value exceeding quality of care and allowing better life and social conditions	Receives the therapy	Recipient	Care
Private	Quality	Involved in self-administration	Active	Value exceeding quality of care of the assisted patient and allowing better life and social conditions	Assists the patient	Recipient	Care of the assisted patient

ISSN: 1472-6963